LRMR Larimar Therapeutics Inc
Price (delayed)
$2.2
Market cap
$140.86M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.32
Enterprise value
$112.15M
Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical
Highlights
The debt has contracted by 8% YoY and by 4.6% from the previous quarter
LRMR's equity has surged by 110% year-on-year but it is down by 13% since the previous quarter
The company's net income has shrunk by 118% YoY and by 24% QoQ
The EPS has plunged by 57% YoY and by 16% from the previous quarter
Key stats
What are the main financial stats of LRMR
Market
Valuations
Earnings
Shares outstanding
64.03M
Market cap
$140.86M
Enterprise value
$112.15M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$90.89M
Net income
-$80.6M
EBIT
-$80.6M
EBITDA
-$80.48M
Free cash flow
-$71.28M
Per share
Balance sheet
Liquidity
EPS
-$1.32
EPS diluted
-$1.32
Free cash flow per share
-$1.16
Book value per share
$2.69
Revenue per share
$0
TBVPS
$3.27
Total assets
$200.23M
Total liabilities
$28.41M
Debt
$5.12M
Equity
$171.81M
Working capital
$170.95M
Debt to equity
0.03
Current ratio
8.02
Quick ratio
7.56
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-35.6%
Return on equity
-39.7%
Return on invested capital
-50.7%
Return on capital employed
-45.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LRMR stock price
How has the Larimar Therapeutics stock price performed over time
Intraday
10%
1 week
-2.22%
1 month
-27.39%
1 year
-70.11%
YTD
-43.15%
QTD
2.33%
Financial performance
How have Larimar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$90.89M
Net income
-$80.6M
Gross margin
N/A
Net margin
N/A
Larimar Therapeutics's operating income has shrunk by 118% YoY and by 23% QoQ
The company's net income has shrunk by 118% YoY and by 24% QoQ
Growth
What is Larimar Therapeutics's growth rate over time
Valuation
What is Larimar Therapeutics stock price valuation
P/E
N/A
P/B
0.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 57% YoY and by 16% from the previous quarter
LRMR's equity has surged by 110% year-on-year but it is down by 13% since the previous quarter
LRMR's P/B is 63% below its last 4 quarters average of 2.0 and 61% below its 5-year quarterly average of 1.9
Efficiency
How efficient is Larimar Therapeutics business performance
The ROIC has soared by 51% YoY but it has contracted by 8% from the previous quarter
LRMR's ROE is down by 11% since the previous quarter and by 2.3% year-on-year
Larimar Therapeutics's ROA has decreased by 10% from the previous quarter and by 3.8% YoY
Dividends
What is LRMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LRMR.
Financial health
How did Larimar Therapeutics financials performed over time
The total assets has soared by 109% YoY but it is down by 9% QoQ
LRMR's total liabilities has surged by 100% year-on-year and by 38% since the previous quarter
The debt is 97% less than the equity
LRMR's equity has surged by 110% year-on-year but it is down by 13% since the previous quarter
LRMR's debt to equity has plunged by 57% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.